December 17, 2021
December 17, 2022 – Dartisla ODT (glycopyrrolate) orally disintegrating tablets have been approved for use as an adjunct to treatment for peptic ulcer in adults to reduce the
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Pharmacy Benefits Management
December 17, 2021
December 17, 2021 – The U.S. FDA has approved Invagen Pharma's lanreotide subcutaneous injection as the first generic version of Ipsen's Somatuline® Depot (lanreotide)
November 19, 2021
November 19, 2021 – The U.S. FDA has expanded emergency use authorization (EUA) for the Pfizer/BioNTech and Moderna COVID-19 vaccines. They can now be used
November 19, 2021
November 19, 2021 – The U.S. FDA has approved VoxzogoTM (vosoritide) for injection to increase linear growth in pediatric patients at least five years of age who have
November 18, 2021
November 18, 2021 – The U.S. FDA is expanding a black box warning, the most prominent warning that can be required on a drug label, for Bayer's Climara
November 15, 2021
November 15, 2021 – Mvasi® (bevacizumab-awwb) has received a new indication to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. The drug, manufactured by Amgen
November 15, 2021
November 15, 2021 – The U.S. FDA has approved a new indication for Ruxience® (rituximab-pvvr), Pfizer's biosimilar for Genentech and Biogen’s Rituxan® (rituximab)
November 15, 2021
November 15, 2021 – PharmaEssentia's Besremi® (ropeginterferon alfa-2b-njft) has been approved to treat polycythemia vera (PV) in adults. It is the only interferon drug FDA approved